Lynkuet evaluation for menopause symptoms in NYC

Lynkuet is elinzanetant, a nonhormonal oral medicine for moderate to severe hot flashes and night sweats due to menopause. It is not estrogen or a sleeping pill. The August 2026 US label includes a seizure precaution that older materials may omit. The usual label regimen is 120 mg, two 60 mg capsules, once daily at bedtime with or without food. Swallow whole with water. A moderate CYP3A4 inhibitor requires a clinician-directed dose adjustment; strong inhibitors, strong or moderate inducers and grapefruit are avoided. Do not select an interaction dose yourself.

No. Lynkuet is elinzanetant, a nonhormonal NK1/NK3 receptor antagonist for moderate-to-severe menopause-related hot flashes and night sweats. It is different from estrogen therapy and from a sleeping pill. Its seizure, CNS, liver, pregnancy and interaction precautions still require an individual review.

The Lynkuet label directs the usual dose at bedtime and warns about CNS effects, including sleepiness and daytime impairment. Bedtime dosing does not make it a sleeping pill or guarantee safe driving the next day. Discuss driving, other sedating medicines and the current seizure warning with the prescriber.

Exclude pregnancy when relevant and obtain baseline ALT, AST, alkaline phosphatase and total and direct bilirubin. Do not start when ALT or AST, or total bilirubin, is at least twice the upper limit of normal. Review medicines, supplements, contraception and seizure history before starting.

Review the menopause-related symptoms, liver and seizure history, medicines and pregnancy possibility. Pregnancy is contraindicated. Moderate or severe hepatic impairment is not a recommended use. Interactions and daytime impairment can make another option more suitable; the clinician selects treatment after the safety review.

Avoid grapefruit and grapefruit juice with Lynkuet under the US label because they can affect CYP3A4-related drug exposure. Strong CYP3A4 inhibitors and certain inducers also need avoidance; moderate inhibitors can require a prescriber-set dose adjustment. Review all medicines and foods with the prescriber or pharmacist rather than changing the dose yourself.

Sleepiness and daytime impairment can affect driving or hazardous tasks; wait until you know the effect and follow the label precautions. Report a seizure or possible liver injury. The label advises stopping and seeking medical attention for liver symptoms. Use effective contraception during treatment and for two weeks after stopping when pregnancy is possible.

Coverage depends on the exact service, product, indication, provider and plan rules. Confirm the clinician and pharmacy route before starting. Visit coverage does not guarantee medication coverage, and manufacturer support or a sample does not guarantee affordable refills. Ask about authorization, testing, costs and follow-up. Confirm whether the selected clinic prescribes the product and whether the pharmacy can fill the exact dose.

Before treatment starts, confirm the diagnosis, the intended benefit, the exact treatment and who will coordinate ongoing care. The usual label regimen is 120 mg, two 60 mg capsules, once daily at bedtime with or without food. Swallow whole with water. A moderate CYP3A4 inhibitor requires a clinician-directed dose adjustment; strong inhibitors, strong or moderate inducers and grapefruit are avoided. Do not select an interaction dose yourself.

Prepare the relevant dated records, current medicine list and your main questions, and confirm any treatment-specific instructions before attending. Exclude pregnancy when relevant and obtain baseline ALT, AST, alkaline phosphatase and total and direct bilirubin. Do not start when ALT or AST, or total bilirubin, is at least twice the upper limit of normal. Review medicines, supplements, contraception and seizure history before starting.

Agree on the next review, how response and safety will be checked, and who to contact for symptoms, missed treatment or a refill problem. Recheck hepatic transaminases at three months and assess symptoms and adverse effects. This differs from Veozah’s liver-test schedule. If a bedtime dose is missed, take the next dose the following day rather than two doses in one day. Review persistent hot flashes, excessive sleepiness or other concerns with the clinician.

The FDA approved Lynkuet (elinzanetant) on October 24, 2025, for moderate-to-severe menopause-related hot flashes. Current prescribing information matters as well as that original date: the August 2026 label includes a seizure precaution, liver assessment and medicine-interaction requirements. Tell the prescriber about seizures, liver disease and all medicines before treatment. It is a nonhormonal oral medicine, but that does not make it appropriate for everyone. FDA approval does not establish stock at a particular pharmacy or prescribing availability at a clinic.